6 January 2026: Japanese patent issued on KazanbodyTM core technology
The patent covering the KazanbodyTM core technology has been issued by the Japan Patent Office (Patent No. 7799325).
1 October 2025: Neko Pharma Awarded the AbbVie Japan Innovation Award & BioLabs Golden Ticket
Neko Pharma has been selected as the winner of the inaugural AbbVie Japan Innovation Award, receiving the prestigious Golden Ticket and a ¥10,000,000 cash prize. Chosen from 26 competitive applications and co-presented by AbbVie GK and U.S.-based BioLabs, the award recognizes our hyperstable protein scaffold platform derived from volcanic bacteria.
Tiago Campos Rodrigues, President of AbbVie GK, announced the winners during a ceremony at AbbVie GK’s headquarters in Minato-ku, Tokyo.
The award includes mentoring support from AbbVie’s in-house R&D and business experts, a ¥10,000,000 cash prize, and one-year complimentary access to BioLabs’ cutting-edge incubation facility, opening in Shin-Kiba in 2026, including major research equipment, services, entrepreneurship programs, and a global researcher community.
The team at Neko Pharma extends their sincere thanks to AbbVie GK and BioLabs for this recognition and their support of Japanese biotech innovation. The mentoring and resources from this award will be invaluable in accelerating our mission to develop next-gen biotherapeutics.
Further details are available in AbbVie’s official press release:
https://www.abbvie.co.jp/content/dam/abbvie-com2/japan/documents/press-release/2025_1001.pdf
2 September 2025: Second patent issued on KazanbodyTM core technology
The second patent covering KazanbodyTM proteins has been issued by the USPTO (Patent No. US 12,404,606 B2).
24 September 2024: Neko Pharma is exhibiting in BioJapan
Neko Pharma will be participating in the Japan Healthcare Venture Summit 2024 to be held in Pacifico Yokohama, Japan, from October 9 to 11, 2024. We are looking forward to meeting you to discuss future opportunities with our KazanbodyTM technology.
For more information on this event, please visit:
https://mediso.mhlw.go.jp/jhvs2024/en/index.html
1 May 2024: Neko Pharma moves to new R&D facilities
The R&D facilities of Neko Pharma have expanded and moved to Todai-Kashiwa Venture Plaza in Chiba Prefecture, Japan.
25 September 2023: Neko Pharma is coming to BioJapan
Neko Pharma will participate in Japan Healthcare Venture Summit 2023 to be held in Pacifico Yokohama, Japan, from October 11 to 13, 2023. Please visit our booth V-10. We are looking forward to meeting you to discuss future opportunities with our KazanbodyTM technology.
For more information on this event, please visit
https://mediso.mhlw.go.jp/jhvs2023/en/index.html
31 January 2023: First patent issued on KazanbodyTM core technology
The first patent covering the KazanbodyTM core technology has been issued by the USPTO (Patent No. US 11,566,346 B2).
15 December 2022: KazanbodyTM exhibits low immunogenicity ex vivo.
The KazanbodyTM scaffold was found to have low immunogenicity in a time course T-cell proliferation assay using 50 donors of diverse HLA allotypes. The proliferation responses induced in response to the KazanbodyTM scaffold (4%) were similar to the low immunogenicity control Herceptin® (6%) showing a low risk of immunogenicity for the KazanbodyTM scaffold.